Revenue Analysis – Global Type 2 Diabetes Mellitus Therapeutics Market Till 2021 - PowerPoint PPT Presentation

Loading...

PPT – Revenue Analysis – Global Type 2 Diabetes Mellitus Therapeutics Market Till 2021 PowerPoint presentation | free to download - id: 803b7d-ZWUxM



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Revenue Analysis – Global Type 2 Diabetes Mellitus Therapeutics Market Till 2021

Description:

Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. – PowerPoint PPT presentation

Number of Views:12

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Revenue Analysis – Global Type 2 Diabetes Mellitus Therapeutics Market Till 2021


1
Type 2 Diabetes Mellitus Therapeutics in Major
Developed Markets to 2021- Strong Pipeline and
Expanding Treatment Population to Encourage
Robust Growth
Published on 03 July, 2015 Number of pages
179 Single User Price 4995
Over the 20142021 forecast period, the Global
T2DM Market is expected to increase in value at a
CAGR of 7.5 from 23.5 Billion to 39.0 Billion.
2
Summary of the Report Type 2 Diabetes Mellitus
(T2DM) is a metabolic disease characterized by
chronic hyperglycemia (high blood glucose
levels). Global prevalence has risen rapidly in
the past several decades, particularly in line
with obesity. This has been attributed to a range
of factors, including economic development,
increasing urbanization, aging populations, and
changes in lifestyle patterns such as reduced
levels of physical activity and consumption of
higher-calorie diets. This has led to strong
commercial interest in the development of T2DM
therapeutics. The current market is large and
diverse, comprising several drug classes,
including generic and branded drugs. Owing to the
range of therapeutic options available, the
treatment algorithm is complex. However, current
treatment regimens are often associated with
limited long-term efficacy, complex and
inconvenient dosing regimens, and undesirable
side effects such as weight gain and hypoglycemia
(low blood glucose levels).
Click Here To Check Complete Report
3
  • Scope of the Report
  • Metformin monotherapy will remain the first-line
    pharmacotherapy for T2DM.
  • The emergence of several new drug classes over
    the past decade, namely the Glucagon-Like
    Peptide-1 (GLP-1) receptor agonists, Dipeptidyl
    Peptidase 4 (DPP-4) inhibitors, and
    SodiumGlucose Cotransporter 2 (SGLT-2)
    inhibitors, has led to considerable market
    growth.
  • Which products lead these drug classes and what
    threats do they face from the pipeline?
  • How will the continued uptake of newer drug
    classes impact established drug classes such as
    the sulfonylureas and thiazolidinediones?
  • Will recently approved insulin therapies such as
    Tresiba (insulin degludec) and Toujeo (insulin
    glargine) be able to capture a significant
    portion of Lantus market share?
  • The pipeline is large and highly innovative,
    comprising a range of molecule types and
    molecular targets.
  • Which late-stage pipeline molecules show the most
    promise and how will they impact the treatment
    algorithm over the forecast period?
  • Over the 20142021 forecast period, the global
    T2DM market is expected to increase in value at a
    CAGR of 7.5 from 23.5 billion to 39.0 billion.

Download Sample Brochure
4
  • Reasons to Buy
  • Understand the clinical context of the T2DM
    indication and the global burden of the disease
    by considering epidemiology, symptoms, etiology,
    pathophysiology, co-morbidities and
    complications, disease classification, disease
    prognosis, and treatment options
  • Appreciate the current T2DM marketed products
    landscape, including the dominant therapeutic
    strategies, products, and companies, and
    recognize gaps within the market and areas of
    unmet need
  • Recognize the late-stage pipeline molecules that
    have demonstrated strong therapeutic potential in
    T2DM by examining clinical trial data and
    multi-scenario product forecast projections
  • Consider market opportunities and potential risks
    by examining trends in T2DM clinical trial size,
    duration, and failure rate by phase of
    development, molecule type, and molecular target
  • Discern variances in treatment usage patterns,
    annual therapy costs, and market growth
    projections for the US, Canada, the UK, France,
    Germany, Italy, Spain, and Japan
  • Discover how strategic consolidations have shaped
    the current T2DM pipeline and marketed products
    landscapes

Make an Inquiry Before Buying
5
Type 2 Diabetes Mellitus Therapeutics in Major
Developed Markets to 2021- Strong Pipeline and
Expanding Treatment Population to Encourage
Robust Growth
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Type 2 Diabetes Mellitus Therapeutics Market
are provided in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Type 2 Diabetes
Mellitus Therapeutics Market Report
About PowerShow.com